<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940817-2-00215</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=84 g=1 f=1 -->  <!-- PJG 0012 frnewline --> Final Report: Principles of Neurotoxicology Risk Assessment  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Contents  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 1. Introduction  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 --> 1.1. Background  <!-- PJG 0012 frnewline --> 1.2. Purpose of This Report  <!-- PJG 0012 frnewline --> 1.3. Context of This Report  <!-- PJG 0012 frnewline --> 1.4. Content of This Report  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 2. Overview of Neurotoxicology  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 --> 2.1. Scope of the Problem  <!-- PJG 0012 frnewline --> 2.1.1. Introduction  <!-- PJG 0012 frnewline --> 2.1.2. Examples of Neurotoxicity and Incidents of Exposure  <!-- PJG 0012 frnewline --> 2.1.3. Federal Response  <!-- PJG 0012 frnewline --> 2.1.3.1. Food and Drug Administration  <!-- PJG 0012 frnewline --> 2.1.3.2. Occupational Safety and Health Administration  <!-- PJG 0012 frnewline --> 2.1.3.3. National Institute for Occupational Safety and Health  <!-- PJG 0012 frnewline --> 2.1.3.4. Environmental Protection Agency  <!-- PJG 0012 frnewline --> 2.1.3.5. Consumer Product Safety Commission  <!-- PJG 0012 frnewline --> 2.1.3.6. Agency for Toxic Substances and Disease Registry  <!-- PJG 0012 frnewline --> 2.2. Basic Toxicological Considerations for Neurotoxicity  <!-- PJG 0012 frnewline --> 2.2.1. Basic Toxicological Principles  <!-- PJG 0012 frnewline --> 2.2.2. Basic Neurotoxicological Principles  <!-- PJG 0012 frnewline --> 2.3. Basic Neurobiological Principles  <!-- PJG 0012 frnewline --> 2.3.1. Structure of the Nervous System  <!-- PJG 0012 frnewline --> 2.3.2. Transport Processes  <!-- PJG 0012 frnewline --> 2.3.3. Ionic Balance  <!-- PJG 0012 frnewline --> 2.3.4. Neurotransmission  <!-- PJG 0012 frnewline --> 2.4. Types of Effects on the Nervous System  <!-- PJG 0012 frnewline --> 2.5. Special Considerations  <!-- PJG 0012 frnewline --> 2.5.1. Susceptible Populations  <!-- PJG 0012 frnewline --> 2.5.2. Blood-Brain and Blood-Nerve Barriers  <!-- PJG 0012 frnewline --> 2.5.3. Metabolism  <!-- PJG 0012 frnewline --> 2.5.4. Limited Regenerative Ability  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 3. Methods for Assessing Human Neurotoxicity  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 --> 3.1. Introduction  <!-- PJG 0012 frnewline --> 3.2. Clinical Evaluation  <!-- PJG 0012 frnewline --> 3.2.1. Neurologic Evaluation  <!-- PJG 0012 frnewline --> 3.2.2. Neuropsychological Testing  <!-- PJG 0012 frnewline --> 3.2.3 Applicability of Clinical Methods to Neurotoxicology Risk Assessment  <!-- PJG 0012 frnewline --> 3.3. Current Neurotoxicity Testing Methods  <!-- PJG 0012 frnewline --> 3.3.1. Neurobehavioral Methods  <!-- PJG 0012 frnewline --> 3.3.1.1. Test Batteries  <!-- PJG 0012 frnewline --> 3.3.1.2. Investigator-Administered Test Batteries  <!-- PJG 0012 frnewline --> 3.3.1.3. Computerized Test Batteries  <!-- PJG 0012 frnewline --> 3.3.2. Neurophysiologic Methods  <!-- PJG 0012 frnewline --> 3.3.3. Neurochemical Methods  <!-- PJG 0012 frnewline --> 3.3.4. Imaging Techniques  <!-- PJG 0012 frnewline --> 3.3.5. Neuropathologic Methods  <!-- PJG 0012 frnewline --> 3.3.6. Self-Report Assessment Methods  <!-- PJG 0012 frnewline --> 3.3.6.1. Mood Scales  <!-- PJG 0012 frnewline --> 3.3.6.2. Personality Scales  <!-- PJG 0012 frnewline --> 3.4. Approaches to Neurotoxicity Assessment  <!-- PJG 0012 frnewline --> 3.4.1. Epidemiologic Studies  <!-- PJG 0012 frnewline --> 3.4.1.1. Case Reports  <!-- PJG 0012 frnewline --> 3.4.1.2. Cross-Sectional Studies  <!-- PJG 0012 frnewline --> 3.4.1.3. Case-Control (Retrospective) Studies  <!-- PJG 0012 frnewline --> 3.4.1.4. Prospective (Cohort, Followup) Studies  <!-- PJG 0012 frnewline --> 3.4.2. Human Laboratory Exposure Studies  <!-- PJG 0012 frnewline --> 3.4.2.1. Methodologic Aspects  <!-- PJG 0012 frnewline --> 3.4.2.2. Human Subject Selection Factors  <!-- PJG 0012 frnewline --> 3.4.2.3. Exposure Conditions and Chemical Classes  <!-- PJG 0012 frnewline --> 3.4.2.4. Test Methods  <!-- PJG 0012 frnewline --> 3.4.2.5. Controls  <!-- PJG 0012 frnewline --> 3.4.2.6. Ethical Issues  <!-- PJG 0012 frnewline --> 3.5. Assessment of Developmental Neurotoxicity  <!-- PJG 0012 frnewline --> 3.5.1. Developmental Deficits  <!-- PJG 0012 frnewline --> 3.5.2. Methodologic Considerations  <!-- PJG 0012 frnewline --> 3.6. Issues in Human Neurotoxicology Test Methods  <!-- PJG 0012 frnewline --> 3.6.1. Risk Assessment Criteria for Neurobehavioral Test Methods  <!-- PJG 0012 frnewline --> 3.6.1.1. Sensitivity  <!-- PJG 0012 frnewline --> 3.6.1.2. Specificity  <!-- PJG 0012 frnewline --> 3.6.1.3. Reliability and Validity  <!-- PJG 0012 frnewline --> 3.6.1.4. Dose Response  <!-- PJG 0012 frnewline --> 3.6.1.5. Structure-Activity  <!-- PJG 0012 frnewline --> 3.6.2. Other Considerations in Risk Assessment  <!-- PJG 0012 frnewline --> 3.6.2.1. Mechanisms of Action  <!-- PJG 0012 frnewline --> 3.6.2.2. Exposure Duration  <!-- PJG 0012 frnewline --> 3.6.2.3. Time-Dependent Effects  <!-- PJG 0012 frnewline --> 3.6.2.4. Multiple Exposures  <!-- PJG 0012 frnewline --> 3.6.2.5. Generalizability and Individual Differences  <!-- PJG 0012 frnewline --> 3.6.2.6. Veracity of Neurobehavioral Test Results  <!-- PJG 0012 frnewline --> 3.6.3. Cross-Species Extrapolation  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 4. Methods to Assess Animal Neurotoxicity  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 --> 4.1. Introduction  <!-- PJG 0012 frnewline --> 4.1.1. Role of Animal Models  <!-- PJG 0012 frnewline --> 4.1.2. Validity of Animal Models  <!-- PJG 0012 frnewline --> 4.1.3. Special Considerations in Animal Models  <!-- PJG 0012 frnewline --> 4.1.3.1. Susceptible Populations  <!-- PJG 0012 frnewline --> 4.1.3.2. Dosing Scenario  <!-- PJG 0012 frnewline --> 4.1.3.3. Other Factors  <!-- PJG 0012 frnewline --> 4.1.3.4. Statistical Considerations  <!-- PJG 0012 frnewline --> 4.2. Tiered Testing in Neurotoxicology  <!-- PJG 0012 frnewline --> 4.2.1. Type of Test  <!-- PJG 0012 frnewline --> 4.2.2. Dosing Regimen  <!-- PJG 0012 frnewline --> 4.3. Endpoints of Neurotoxicity  <!-- PJG 0012 frnewline --> 4.3.1. Introduction  <!-- PJG 0012 frnewline --> 4.3.2. Behavioral Endpoints  <!-- PJG 0012 frnewline --> 4.3.2.1. Functional Observational Batteries  <!-- PJG 0012 frnewline --> 4.3.2.2. Motor Activity  <!-- PJG 0012 frnewline --> 4.3.2.3. Neuromotor Function  <!-- PJG 0012 frnewline --> 4.3.2.4. Sensory Function  <!-- PJG 0012 frnewline --> 4.3.2.5. Learning and Memory  <!-- PJG 0012 frnewline --> 4.3.2.6. Schedule-Controlled Behavior  <!-- PJG 0012 frnewline --> 4.3.3. Neurophysiological Endpoints of Neurotoxicity  <!-- PJG 0012 frnewline --> 4.3.3.1. Nerve Conduction Studies  <!-- PJG 0012 frnewline --> 4.3.3.2. Sensory Evoked Potentials  <!-- PJG 0012 frnewline --> 4.3.3.3. Convulsions  <!-- PJG 0012 frnewline --> 4.3.3.4. Electroencephalography  <!-- PJG 0012 frnewline --> 4.3.3.5. Electromyography  <!-- PJG 0012 frnewline --> 4.3.3.6. Spinal Reflex Excitability  <!-- PJG 0012 frnewline --> 4.3.4. Neurochemical Endpoints of Neurotoxicity  <!-- PJG 0012 frnewline --> 4.3.5. Structural Endpoints of Neurotoxicity  <!-- PJG 0012 frnewline --> 4.3.6. Developmental Neurotoxicity  <!-- PJG 0012 frnewline --> 4.3.7. Physiological and Neuroendocrine Endpoints  <!-- PJG 0012 frnewline --> 4.3.8. Other Considerations  <!-- PJG 0012 frnewline --> 4.3.8.1. Structure-Activity Relationship  <!-- PJG 0012 frnewline --> 4.3.8.2. In Vitro Methods  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 5. Neurotoxicology Risk Assessment  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 --> 5.1. Introduction  <!-- PJG 0012 frnewline --> 5.2. The Risk Assessment Process  <!-- PJG 0012 frnewline --> 5.2.1. Hazard Identification  <!-- PJG 0012 frnewline --> 5.2.1.1. Human Studies  <!-- PJG 0012 frnewline --> 5.2.1.2. Animal Studies  <!-- PJG 0012 frnewline --> 5.2.1.3. Special Issues  <!-- PJG 0012 frnewline --> 5.2.2. Dose-Response Assessment  <!-- PJG 0012 frnewline --> 5.2.3. Exposure Assessment  <!-- PJG 0012 frnewline --> 5.2.4. Risk Characterization  <!-- PJG 0012 frnewline --> 5.3. Generic Assumptions and Uncertainty Reduction  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 6. General Summary  <!-- PJG 0012 frnewline --> 7. References <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=81 g=1 f=1 --> Tables  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> 1&hyph;1. Major Regulatory Agencies  <!-- PJG 0012 frnewline --> 1&hyph;2. Authorities for Toxicity Testing  <!-- PJG 0012 frnewline --> 2&hyph;1. Human Neurotoxic Exposures  <!-- PJG 0012 frnewline --> 3&hyph;1. Neurobehavioral Methods  <!-- PJG 0012 frnewline --> 4&hyph;1. Examples of Potential Endpoints of Neurotoxicity  <!-- PJG 0012 frnewline --> 4&hyph;2. Examples of Specialized Tests to Measure Neurotoxicity  <!-- PJG 0012 frnewline --> 4&hyph;3. Summary of Measures in the Functional Observational Battery and the Type of Data Produced by Each  <!-- PJG 0012 frnewline --> 4&hyph;4. Neurotoxicants With Known Neurochemical Mechanisms  <!-- PJG 0012 frnewline --> 4&hyph;5. Examples of Known Neuropathic Agents  <!-- PJG 0012 frnewline --> 4&hyph;6. Partial List of Agents Believed to Have Developmental Neurotoxicity  <!-- PJG 0012 frnewline --> 5&hyph;1. General Assumptions That Underlie Traditional Risk Assessments  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            